Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03928314 · ClinicalTrials.gov registry record · Phase 1
Study of ORIC-101 in Combination With Anticancer Therapy
A Phase 1 study, sponsored by ORIC Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 83
- Enrollment target
NCT03928314: Clinical Trial Phase 1 study, sponsored by ORIC Pharmaceuticals.
NCT03928314 is a Phase 1 study that was terminated before completion, run by ORIC Pharmaceuticals. The registered enrollment target is 83 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (38% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03928314, a Phase 1 study, was terminated before completion, sponsored by ORIC Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 83 participants
- Enrollment target
Study Summary
The purpose of this study is to establish the recommended Phase 2 dose (RP2D), safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of ORIC-101 in combination with nab-paclitaxel or other anticancer therapies when administered to patients with advanced or metastatic solid tumors.
Primary Outcome
RP2D as determined by 3+3 dose escalation design
Interventions
- DRUG Nab-paclitaxel
- DRUG ORIC-101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 83 participants |
| Start Date | 2019-05-02 |
| Est. Completion | 2023-12-04 |
| Phase | Phase 1 |
Why NCT03928314 stopped before completion
NCT03928314 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 83 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (38% higher).
The record links to 0 conditions, and to 2 interventions - of which Nab-paclitaxel is the first listed.
NCT03928314 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03928314 about?
NCT03928314 is a clinical study titled "Study of ORIC-101 in Combination With Anticancer Therapy". The purpose of this study is to establish the recommended Phase 2 dose (RP2D), safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of ORIC-101 in combination with nab-paclitaxel or other anticancer therapies when administered to patients with advanced or metastat...
What is the current status of trial NCT03928314?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 83 participants. The study started on 2019-05-02. Estimated completion is 2023-12-04.
What interventions are being tested in trial NCT03928314?
The interventions under investigation include: Nab-paclitaxel (DRUG), ORIC-101 (DRUG).
Who is sponsoring clinical trial NCT03928314?
This trial is sponsored by ORIC Pharmaceuticals, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03928314's enrollment target sits among peer trials
83 665th of 2000 higher than 1,332 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02974647 · 83 participants · Phase 2
Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma
- NCT03919292 · 83 participants · Phase 1
Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca
- NCT04626674 · 83 participants · Phase 1
A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)
- NCT05277168 · 83 participants · Phase 1
A Trial TO Evaluate THE Safety, Tolerability, Pharmacokinetics, AND Efficacy OF Shr-a1904 IN Subjects With Advanced Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI